robenacoxib
Selected indexed studies
- Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy. (Vet Med (Auckl), 2018) [PMID:30148083]
- Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. (J Vet Pharmacol Ther, 2022) [PMID:35460083]
- 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats. (J Feline Med Surg, 2024) [PMID:38587872]
_Worker-drafted node — pending editorial review._
Connections
robenacoxib is a side effect of
Sources
- Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy. (2018) pubmed
- Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. (2022) pubmed
- 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats. (2024) pubmed
- Evaluation of cats treated with robenacoxib after gastrointestinal surgery. (2024) pubmed
- Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration. (2022) pubmed
- Clinical safety of robenacoxib in cats with chronic musculoskeletal disease. (2021) pubmed
- Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial. (2021) pubmed
- Pharmacokinetics of robenacoxib after a single intramuscular dose in smooth dogfish (Mustelus canis). (2023) pubmed
- Robenacoxib versus meloxicam following ovariohysterectomy in cats: A randomised, prospective clinical trial involving owner-based assessment of pain. (2023) pubmed
- Effects of selective cyclooxygenase-2 inhibitor robenacoxib on primary cells derived from feline injection-site sarcoma. (2023) pubmed